New hybrid closed loop technology with lower target blood glucose

The Twiist automated insulin delivery (AID) system, developed by Sequel Med Tech, is expected to become commercially available in Q2 2025. Notably, this system allows for a target blood glucose as low as 87 mg/dL. This feature may be particularly relevant for pregnant patients, where tighter glucose targets are often necessary. In comparison, other hybrid closed-loop systems typically have target ranges between 100–110 mg/dL. Therefore, a system like Twiist—with the capability for lower glucose targets—could better align with the physiological needs of pregnancy and support improved glycemic control during this critical period. "With its ability to target blood glucose levels as low as 87 mg/dL, the Twiist AID system represents a promising advancement for pregnant individuals requiring tighter glycemic control—bringing technology closer to the physiological demands of pregnancy than ever before.", says Dr. Crimmins.

“Anything that helps patients spend more time in a healthy blood glucose range will lead to better outcomes for all.”